Global Extended Release Drugs Market Report 2024

Extended-Release Drugs Global Market Report 2024 – By Type (Sustained Release Drug, Controlled Release Drug), By Mode (Over-The-Counter, Prescription), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Extended-Release Drugs Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Extended-Release Drugs Market Definition And Segments

Extended-release drugs are a dosage form made to release the medication over a longer time, at a predetermined rate, duration, and location, in a controlled manner. The drug can be taken less frequently than the immediate release form, and patients may take 1 to 2 doses each day instead of 3 to 4.

The main types of extended-release drugs are sustained-release drugs and controlled-release drugs. Sustained release drug refers to medication that is intended to slowly release in the body over time, primarily to maintain therapeutic levels. They are available as over-the-counter and prescription modes and distributed by hospital pharmacies, retail pharmacies, mail-order pharmacies, and drug store channels.

The extended-release drugs market covered in this report is segmented –

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

The extended-release drugs market size has grown rapidly in recent years. It will grow from $57.11 billion in 2023 to $63.82 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to patient compliance improvement, chronic disease prevalence, improved efficacy, patent protection strategy, biodegradable implants.

The extended-release drugs market size is expected to see rapid growth in the next few years. It will grow to $99.77 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to personalized medicine approaches, patient-centric drug development, rising incidence of lifestyle diseases, drug repurposing, global access to extended-release therapies. Major trends in the forecast period include pharmaceutical innovation, advancements in drug delivery systems, advancements in nanotechnology, 3d printing in drug formulations, use of artificial intelligence, environmental sustainability.

Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market

The increasing incidence of chronic conditions is expected to propel the growth of the extended-release drug market going forward. Chronic conditions are defined as conditions that last for a year or longer and necessitate continuing medical care, restricting everyday activities, or both. Heart disease, cancer, obesity, and diabetes are a few examples. Extended-release drug delivery systems are designed to provide a relatively constant level of medication in the body over a long period. It helps maintain a consistent therapeutic effect and avoids the fluctuations in drug levels that can occur with immediate-release medications. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Therefore, the increasing incidence of chronic conditions is driving the growth of the extended-release drug market.

The Surging Demand For Extended-Release Drugs In Response To Pharmaceutical Industry Growth

The increasing demand for pharmaceutical industry is expected to propel the growth of the extended-release drugs market going forward. The pharmaceutical industry is a sector of the healthcare industry that focuses on the discovery, development, production, and marketing of drugs and medications. Extended-release drugs contribute to improved patient compliance, enhanced therapeutic outcomes, reduced frequency of administration, steady drug levels in the bloodstream, minimized side effects, reduced fluctuations in symptoms and a better overall pharmaceutical experience. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a European trade association representing the pharmaceutical industry, the total pharmaceutical production in Europe accounted for $384,200 million (€340,000 million) in 2022, with an increase of approximately 4.95% from 366,267 million (€323,950 million) in 2021. Therefore, the increasing demand for pharmaceutical industry is driving the growth of the extended-release drugs market.

Major companies operating in the extended-release drugs market report are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca PLC, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan PLC, AVEVA Group PLC, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

Pioneer In Epilepsy Treatment Innovation

Product innovation is a key trend gaining popularity in the extended-release drug market. Major companies operating in the extended-release drug market are developing innovative products to sustain their position in the market. For instance, in July 2022, Zydus Pharmaceuticals (USA) Inc., a US-based generic pharmaceutical manufacturer, launched Topiramate extended-release capsules for epilepsy. The US Food and Drug Administration (USFDA) has previously approved the company to commercialize Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. It is the first business in the country to obtain final approval and introduce Topiramate extended-release capsules. Topiramate extended-release tablets are approved in two ways for individuals with partial onset or primary generalized tonic-clinic seizure.

Extended-Release Tablets For Enhanced Treatment Of Huntington Disease-Related Movement Disorders

Major companies operating in the extended-release drugs market are developing innovative products such as next-generation extended-release tablets to enhance product offerings and gain a competitive advantage. Extended-release tablets are a type of pharmaceutical formulation designed to release their active ingredients gradually over an extended period. For instance, in February 2023, Teva Pharmaceutical Industries Ltd. an Israel-based pharmaceutical company received approval from the U.S. Food and Drug Administration (FDA) for austedo XR (deutetrabenazine). Austedo XR is recommended for the treatment of adults with chorea and tardive dyskinesia related to Huntington disease. They come in dosages of 6, 12, and 24 mg. With the approval of austedo XR, patients with tardive dyskinesia and Huntington disease chorea now have another efficient treatment option. This allows individuals to live with these disorders and the medication is administered once daily. The development of austedo XR, which provides a practical and efficient therapeutic alternative for those with certain movement disorders, signifies a significant leap in the management of these ailments.

Pfizer Expands Portfolio Through Acquisition Of Arena Pharmaceuticals

In March 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Arena Pharmaceuticals for approximately $6.7 billion. With this acquisition, Pfizer gains access to various exciting and promising development-stage pharmaceutical prospects from Arena Pharmaceuticals in cardiology, dermatology, and gastroenterology. Arena Pharmaceuticals is a US-based biopharmaceutical company with small-molecule extended-release medications under development for potential clinical use in various therapeutic fields.

North America was the largest region in the extended-release drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the extended-release drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The extended-release drug market consists of sales of extended-release tablets, extended-release capsules, and implants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The extended-release drugs research report is one of a series of new reports from The Business Research Company that provides extended-release drugs market statistics, including the extended-release drugs industry's global market size, regional shares, competitors with extended-release drugs market share, detailed extended-release drugs market segments, market trends and opportunities, and any further data you may need to thrive in the extended-release drugs industry. This extended-release drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Extended-Release Drugs Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $63.82 billion
Revenue Forecast In 2033 $99.77 billion
Growth Rate CAGR of 11.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Pfizer Inc.; AbbVie Inc.; Novartis AG; Sanofi SA; GlaxoSmithKline PLC; AstraZeneca Plc; Gilead Sciences Inc.; Boehringer Ingelheim International GmbH; Viatris Inc.; Teva Pharmaceuticals Inc.; Eastman Chemical Company; Catalent Pharma Solutions Inc.; Catalent Pharma Solutions Inc; Sun Pharmaceutical Industries Limited; Purdue Pharma LP; Amneal Pharmaceuticals Inc.; Endo Pharmaceuticals Inc.; Mallinckrodt LLC; Allergan plc; AVEVA Group PLC; Hisamitsu Pharmaceutical Co. Inc.; Janssen Pharmaceuticals Inc.; Noven Pharmaceuticals Inc.; Mayne Pharma Group Ltd.; Neos Therapeutics Inc.; Ardena Holding NV; UPM Pharmaceuticals Inc.; Oakwood Laboratories LLC; Roxane Laboratories Inc.; Lavipharm Laboratories Inc.; Watson Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Extended-Release Drugs Market Characteristics

    3. Extended-Release Drugs Market Trends And Strategies

    4. Extended-Release Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Extended-Release Drugs Market Size and Growth

    5.1. Global Extended-Release Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Extended-Release Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Extended-Release Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Extended-Release Drugs Market Segmentation

    6.1. Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Sustained Release Drug

    Controlled Release Drug

    6.2. Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Over-The-Counter

    Prescription

    6.3. Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacies

    Retail Pharmacies

    Mail Order Pharmacies

    Drug Stores

    7. Extended-Release Drugs Market Regional And Country Analysis

    7.1. Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Extended-Release Drugs Market

    8.1. Asia-Pacific Extended-Release Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Extended-Release Drugs Market

    9.1. China Extended-Release Drugs Market Overview

    9.2. China Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Extended-Release Drugs Market

    10.1. India Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Extended-Release Drugs Market

    11.1. Japan Extended-Release Drugs Market Overview

    11.2. Japan Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Extended-Release Drugs Market

    12.1. Australia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Extended-Release Drugs Market

    13.1. Indonesia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Extended-Release Drugs Market

    14.1. South Korea Extended-Release Drugs Market Overview

    14.2. South Korea Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Extended-Release Drugs Market

    15.1. Western Europe Extended-Release Drugs Market Overview

    15.2. Western Europe Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Extended-Release Drugs Market

    16.1. UK Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Extended-Release Drugs Market

    17.1. Germany Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Extended-Release Drugs Market

    18.5. France Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Extended-Release Drugs Market

    19.9. Italy Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Extended-Release Drugs Market

    20.13. Spain Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Extended-Release Drugs Market

    21.1. Eastern Europe Extended-Release Drugs Market Overview

    21.2. Eastern Europe Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Extended-Release Drugs Market

    22.1. Russia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Extended-Release Drugs Market

    23.1. North America Extended-Release Drugs Market Overview

    23.2. North America Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Extended-Release Drugs Market

    24.1. USA Extended-Release Drugs Market Overview

    24.2. USA Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Extended-Release Drugs Market

    25.1. Canada Extended-Release Drugs Market Overview

    25.2. Canada Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Extended-Release Drugs Market

    26.1. South America Extended-Release Drugs Market Overview

    26.2. South America Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Extended-Release Drugs Market

    27.1. Brazil Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Extended-Release Drugs Market

    28.1. Middle East Extended-Release Drugs Market Overview

    28.2. Middle East Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Extended-Release Drugs Market

    29.1. Africa Extended-Release Drugs Market Overview

    29.2. Africa Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Extended-Release Drugs Market Competitive Landscape And Company Profiles

    30.1. Extended-Release Drugs Market Competitive Landscape

    30.2. Extended-Release Drugs Market Company Profiles

    30.2.1. Pfizer Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. AbbVie Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Novartis AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Sanofi SA

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. GlaxoSmithKline PLC

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Extended-Release Drugs Market Other Major And Innovative Companies

    31.1. AstraZeneca Plc

    31.2. Gilead Sciences Inc.

    31.3. Boehringer Ingelheim International GmbH

    31.4. Viatris Inc.

    31.5. Teva Pharmaceuticals Inc.

    31.6. Eastman Chemical Company

    31.7. Catalent Pharma Solutions Inc.

    31.8. Catalent Pharma Solutions Inc

    31.9. Sun Pharmaceutical Industries Limited

    31.10. Purdue Pharma LP

    31.11. Amneal Pharmaceuticals Inc.

    31.12. Endo Pharmaceuticals Inc.

    31.13. Mallinckrodt LLC

    31.14. Allergan plc

    31.15. AVEVA Group PLC

    32. Global Extended-Release Drugs Market Competitive Benchmarking

    33. Global Extended-Release Drugs Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Extended-Release Drugs Market

    35. Extended-Release Drugs Market Future Outlook and Potential Analysis

    35.1 Extended-Release Drugs Market In 2028 - Countries Offering Most New Opportunities

    35.2 Extended-Release Drugs Market In 2028 - Segments Offering Most New Opportunities

    35.3 Extended-Release Drugs Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Pfizer Inc. Financial Performance
  • Table 75: AbbVie Inc. Financial Performance
  • Table 76: Novartis AG Financial Performance
  • Table 77: Sanofi SA Financial Performance
  • Table 78: GlaxoSmithKline PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Pfizer Inc. Financial Performance
  • Figure 75: AbbVie Inc. Financial Performance
  • Figure 76: Novartis AG Financial Performance
  • Figure 77: Sanofi SA Financial Performance
  • Figure 78: GlaxoSmithKline PLC Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Extended Reality Global Market Report 2024 – By Component (Hardware, Software, Services), By Technologies (Augmented Reality (AR) Technology, Virtual Reality (VR) Technology, Mixed Reality (MR) Technology), By End User (Gaming, Retail, Healthcare, Manufacturing, Media And Entertainment, Education, Aerospace And Defense, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Drugs of Abuse (DOA) Testing Global Market Report 2024 – By Product And Service (Analyzers, Rapid Testing Devices, Consumables, Laboratory Services), By Sample Type (Urine, Hair, Oral Fluid, Breath), By Application (Pain Management, Criminal Justice, Workplace Screening), By End User (Hospitals, Diagnostic Laboratories, Forensic Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Drugs For Benign Prostatic hypertrophy Global Market Report 2024 – By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospital Pharmacies, Retail Pharmacies, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Drugs For Hormonal Replacement Therapy Global Market Report 2024 – By Therapy Type (Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Drugs for Immunotherapy Global Market Report 2024 – By Type (Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types), By Therapy Area (Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Controlled Release Fertilizer Global Market Report 2024 – By Type (Slow Release, Nitrogen Stabilizers, Coated And Encapsulated), By Form (Liquid, Granular, Powder), By Application (Foliar, Fertigation, Soil, Other Applications), By End Use (Grains And Cereals, Pulses And Oilseeds, Commercial Crops, Fruits And Vegetables, Turf And Ornamentals, Other End Uses) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Controlled Release Drug Delivery Global Market Report 2024 – By Technology (Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies), By Release Mechanism (Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated, ), By Application (Metered Dose Inhalers, Injectable, Transdermal and Ocular Patches, Other Applications), By End User (Hospitals, Clinics, Personal, Research, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Sustained Release Excipients Global Market Report 2024 – By Product (Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan), By Route of Administration (Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration), By Technology (Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation) – Market Size, Trends, And Global Forecast 2024-2033
View Report

Frequently Asked Questions

What is the definition of the extended-release drugs market?

Extended-release drugs are a dosage form made to release the medication over a longer time, at a predetermined rate, duration, and location, in a controlled manner. The drug can be taken less frequently than the immediate release form, and patients may take 1 to 2 doses each day instead of 3 to 4. For further insights on the extended-release drugs market, request a sample here

How will the extended-release drugs market drivers and restraints affect the extended-release drugs market dynamics? What forces will shape the extended-release drugs industry going forward?

The extended-release drugs market major growth driver - Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market. For further insights on the extended-release drugs market, request a sample here

What is the forecast market size or the forecast market value of the extended-release drugs market?

The extended-release drugs market size has grown rapidly in recent years. It will grow from $57.11 billion in 2023 to $63.82 billion in 2024 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to patient compliance improvement, chronic disease prevalence, improved efficacy, patent protection strategy, biodegradable implants. The extended-release drugs market size is expected to see rapid growth in the next few years. It will grow to $99.77 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to personalized medicine approaches, patient-centric drug development, rising incidence of lifestyle diseases, drug repurposing, global access to extended-release therapies. Major trends in the forecast period include pharmaceutical innovation, advancements in drug delivery systems, advancements in nanotechnology, 3d printing in drug formulations, use of artificial intelligence, environmental sustainability. For further insights on the extended-release drugs market, request a sample here

How is the extended-release drugs market segmented?

The extended-release drugs market is segmented
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug StoresFor further insights on the extended-release drugs market, request a sample here

Which region has the largest share of the extended-release drugs market? What are the other regions covered in the report?

North America was the largest region in the extended-release drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the extended-release drugs market, request a sample here.

Who are the major players in the extended-release drugs market?

Major companies operating in the extended-release drugs market report are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Catalent Pharma Solutions Inc, Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, AVEVA Group PLC, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc. For further insights on the extended-release drugs market, request a sample here.

What are the key trends in the extended-release drugs market?

Major trend in the extended-release drugs market - Pioneer In Epilepsy Treatment Innovation. For further insights on the extended-release drugs market, request a sample here.

What are the major opportunities in the extended-release drugs market? What are the strategies for the extended-release drugs market?

For detailed insights on the major opportunities and strategies in the extended-release drugs market, request a sample here.

How does the extended-release drugs market relate to the overall economy and other similar markets?

For detailed insights on extended-release drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the extended-release drugs industry?

For detailed insights on the mergers and acquisitions in the extended-release drugs industry, request a sample here.

What are the key dynamics influencing the extended-release drugs market growth? SWOT analysis of the extended-release drugs market.

For detailed insights on the key dynamics influencing the extended-release drugs market growth and SWOT analysis of the extended-release drugs industry, request a sample here.